Hepatocyte growth factor - Kringle Pharma

Drug Profile

Hepatocyte growth factor - Kringle Pharma

Alternative Names: KP-100IT

Latest Information Update: 29 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kringle Pharma
  • Developer Keio University School of Medicine; Kringle Pharma
  • Class Antifibrotics; Growth factors; Neuropsychotherapeutics
  • Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Cell death inhibitors; Proto oncogene protein c met modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis
  • Phase I/II Scars; Spinal cord injuries
  • Phase I Acute kidney injury
  • No development reported Renal failure

Most Recent Events

  • 29 Dec 2016 Phase-I clinical trials in Acute kidney injury in USA before December 2016 (Kringle Pharma website, December 2016)
  • 29 Dec 2016 Phase-I/II clinical trials in Scars in Japan before December 2016 (Kringle Pharma pipeline, December 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Renal-failure in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top